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In order to explore novel therapeutic opportunities for B-cell malignancies, we evaluated the effects of MEK inhibitors (MEKi) on chronic lymphocytic leukaemia (CLL). We found that none had a significant effect on CLL viability, despite inhibiting signalling.
Paradoxically, MEKi promoted the accumulation of active MEK and CRAF, reduced the expression of negative regulators of the pathway and augmented AKT signalling. Combining MEKi and PI3K inhibitors antagonized this effect and induced cell death. We propose that MEKi-mediated activation of pro-survival pathways explains their low toxicity in CLL and that inhibition of both RAF/MEK/ERK and PI3K/AKT signalling could overcome single-agent resistance.
The RAF/MEK/ERK signalling cascade is activated in nearly half of the CLL patients, suggesting a pathogenic role (Muzio, et al 2008) . Selective inhibitors have been developed, including MEK1/2 inhibitors (MEKi) that are being clinically assessed as a monotherapy or in combination. However, MEKi have a lower efficiency in cancers not driven by mutant BRAF or KRAS, due to resistance mechanisms. This has limited the clinical use of these compounds.
To test the effects of blocking the RAF/MEK/ERK pathway in CLL, we used different MEKi (U0126, PD0325901, selumetinib and trametinib) on MEC-1, a cell line often used as a model for CLL, in which we observed increased RAF/MEK/ERK signalling .
We used sorafenib (pan-RAF inhibitor) and dabrafenib (BRAF inhibitor) for comparison.
MEKi did not affect the viability ( Figure 1A ), survival ( Figure S1A ), cell cycle profile ( Figure   S1B ), Mcl-1 levels or PARP cleavage ( Figure S1C ) in MEC-1, and only very high concentrations of sorafenib decreased Mcl-1 expression, cleaved PARP and induced death in MEC-1 ( Figure 1A , S1A-C). Similar results were observed in JVM3, a B-prolymphocytic leukaemia cell line ( Figure S1D ). In contrast, the viability of SIG-M5, an acute myeloid leukaemia cell line with a BRAF mutation, was reduced ( Figure S1D) , consistent with the known sensitivity of BRAF-driven malignancies to RAF/MEK/ERK inhibition. In primary cells stimulated with CD40L/IL-4 to mimic the microenvironment of proliferation centres, MEKi did not reduce viability either ( Figure 1B ). This suggests that MEKi do not affect survival of CLL cells at pharmacologically relevant doses.
We found that the downstream phosphorylation of ERK (on Thr202 and Tyr204) in MEC-1 was abolished by MEKi, as expected ( Figure 1C ). However, MEKi induced Ser218/222 phosphorylated MEK, suggesting an upstream reactivation of the pathway. This was also the case in patient cells stimulated with CD40L/IL-4 ( Figure 1D ) or co-cultured with NTL/CD154/IL-4 ( Figure S2A ). Of note, sorafenib and dabrafenib reduced the phosphorylation of both MEK and ERK ( Figures 1C and D) .
BRAF-CRAF dimerization reactivates ERK signalling in BRAF-wild type cells treated with BRAF-specific inhibitors. Moreover, BRAF-CRAF dimerization is required for RAF activation. Thus, we reasoned that MEKi-triggered MEK phosphorylation could be due to RAF reactivation. However, MEKi did not promote dimer formation, although sorafenib was able to enhance it ( Figure 2A ). MEKi treatment did not change the activating phosphorylation of BRAF (Ser445), but it either increased phosphorylated Ser338 in CRAF, which is related to activation, and/or decreased its inhibitory Ser289/296/301 phosphorylation ( Figure 2B ). This is consistent with ERK being inhibited in response to MEKi. MEKi did not change the expression of PP2A, which regulates the RAF/MEK/ERK by dephosphorylating CRAF ( Figure   S2B ). This shows that MEKi reactivate CRAF, which could mediate the accumulation of MEK.
We next examined the effects of MEKi on negative regulators of the pathway. We found that MEKi decreased SPRED1/2, SPRY2 and DUSP4/5/6 in a dose-dependent manner ( Figure 2C ). Downregulation of all these modulators could also be contributing to the reactivation of upstream RAF/MEK/ERK signalling.
We also found that selumetinib activated AKT ( Figure 2D ), as did trametinib, although at higher concentrations the effect was reversed. This suggested that AKT could contribute to MEKi resistance. To test this, we used CUDC907, which inhibits HDACs and PI3K. The combination of MEKi and CUDC907 suppressed ERK and AKT signalling, as expected ( Figure 2E ). Low concentrations of CUDC907 did not induce cell death in MEC-1 ( Figure 2F ), but when combined with non-toxic concentrations of selumetinib, cell death increased to 40-50%. This shows that a non-lethal suppression of PI3K turns MEK inhibition into apoptosis in CLL. This was confirmed with trametinib and idelalisib, a specific PI3K δ inhibitor ( Figure   S2C ). The effect was not observed when two RAF/MEK/ERK inhibitors were combined ( Figure S2D ).
We propose that MEKi induce upstream RAF/MEK/ERK signalling in CLL by reactivating RAF through downregulation of SPRY and DUSP proteins, leading to phosphorylation of CRAF. This results in activation of pro-survival pathways, including AKT, and drug resistance. Precision medicines have changed the prognosis of blood malignancies but their use is hampered by resistance, hence the need to find parameters that allow the stratification of patients (Dyer, et al 2013) . We propose that understanding ERK-dependent signalling feedback is important to design new CLL therapies. Use of MEKi as single agents should be discouraged because the activation of pro-survival signals may compensate the effect. Combination therapies of MEKi with PI3K inhibitors could provide instead a novel therapeutic strategy. (Meads, et al 2008 , Pleyer, et al 2009 . Cells were stimulated under these conditions for 24 hours before treatments. Established cells lines were cultured as previous described . RAF inhibitor sorafenib and MEK inhibitors U0126, PD0352901, selumetinib, trametinib and CUDC907 were obtained from Selleckchem (Houston, TX, USA).
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Assessment of cell viability and death. Cell viability was assessed by measuring themetabolic activity of cells using the CellTiter 96 Aqueous One Solution Cell Proliferation MTS Assay (Promega), following the manufacturer's instructions as previously described . The absorbance at 490 nm was recorded on a TECAN infinite F50 reader (Labtech International). These experiments were performed in triplicate and repeated on at least two independent occasions. Cell death was measured by staining with propidium iodide (PI) for 30 min at 4°C and the percentage of PI-positive cells (dead) determined by flow cytometry using a FACS Canto II cytometer (BD Biosciences).
Cell-cycle analysis. Cells were harvested, fixed with precooled 70% ethanol at -20°C overnight, and then stained with PI (Sigma-Aldrich) diluted in PBS containing RNase A at 37°C for 30 minutes in the dark. Cell-cycle distribution was then determined by flow cytometry.
Western blotting. Total protein was extracted from cells lysates using RIPA lysis buffer and loading buffer as previous described . Proteins were separated with SDS- antibodies were also used. Fluorescent-conjugated anti-rabbit or anti-mouse secondary antibodies were purchased from Enzo life sciences (Farmingdale, NY, USA).
Co-immunoprecipitation. 2×10
7 MEC-1 cells were washed with pre-chilled PBS and lysed with 0.5-1.0 ml pre-chilled NP-40 cell lysis buffer (50 mM Tris-HCl pH8.0, 150 mM NaCl, 1%
(v/v) NP-40) and incubated on ice for 10 min, then sonicated using a Jencons untrasonic processor with microtip for 10 min in ice-water bath. The supernatant was aliquoted and incubated with specific BRAF and CRAF antibodies rocking overnight at 4 °C. Antibodyprotein complexes were then precipitated with 50 μl Protein A-Sepharose beads (Santa Cruz) for 1-3 h. Collected precipitates were extensive washed with IP-washing buffer (10 mM Tris-3 HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 1 mM EGTA and 0.2 mM Na3VO4). Proteins were finally eluted from beads by loading buffer and boiled at 95-100 °C for 10 min.
qRT-PCR analysis. RNA was extracted using the ReliaPrepTM RNA Cell Miniprep System (Promega). Total RNA was reversely transcribed using Thermo Script reverse transcriptase (SuperScript III First-Strand Synthesis System; Invitrogen). Quantitative real-time PCR was performed on a Roche LightCycler using the sensiMix SYBR No-Rox kit following the manufacturer's protocol. Experiments were performed in triplicate. The primer sets used were designed using PrimerBank (Wang, et al 2012) . For the complete primer list, see
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